Quantcast

Latest Bioethics Stories

2014-01-22 23:23:03

Xtalks presents an exciting live webinar on Thursday, February 13, 2014 at 11:00am EST (16:00 GMT). Join keynote speakers Aysha Akhtar, Fellow, Oxford Centre for Animal Ethics, and Medical Officer, Food and Drug Administration, and Dr. Toby Gill, Independent Nanotechnology Professional, UK, for a one-hour discussion on alternatives to animal testing methods. Toronto, Canada (PRWEB) January 22, 2014 The presenters will discuss scientific and ethical imperatives associated with the use of...

2014-01-20 23:04:09

GIA announces the release of a trend report on Designer Babies. The concept of Designer Babies is gaining in popularity driven by developments in genetic engineering that help scientists to screen embryos for genetic disorders to artificially make babies with desired personal and genetic traits. San Jose, California (PRWEB) January 20, 2014 Follow us on LinkedIn – Designer babies are defined as babies with artificial genetic makeup selected through a combination of genetic engineering...

2014-01-17 12:25:10

WASHINGTON, Jan. 17, 2014 /PRNewswire-USNewswire/ -- As you line up interviews and segments for Life News this month, Americans United for Life President and CEO Dr. Charmaine Yoest, along with other members of AUL's legal and political team, are the right choice for analysis and insight into the most current trends related to abortion's 40-plus year legacy and impact. Today in Rolling Stone, AUL and Dr. Yoest were featured in an in-depth story on the legislative strategy that is...

2014-01-16 08:26:49

Receipt of Proceeds increases January Cash Position to Approximately $6.6 million PRINCETON, N.J., Jan. 16, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of...

2014-01-09 16:25:37

OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this...

Placebo Effect Enhances Migraine Drug
2014-01-09 08:33:52

redOrbit Staff & Wire Reports - Your Universe Online A new study of migraine sufferers is the latest to demonstrate the remarkable power of the placebo effect, finding that what a doctor tells you when prescribing medicine can influence your body's response to it. The study, published Wednesday in the journal Science Translational Medicine, compared the effects of the common migraine drug Maxalt (rizatriptan) to an inactive placebo (sugar pill) in 66 sufferers of chronic migraine...

2014-01-08 23:22:27

RnRMarketResearch.com adds “Mice Model Market – by Type [Inbred, Knockout, Conditioned], Technology [Microinjection, Embryonic Stem Cell], Disease [Oncology, Immunology, CNS], Service [Breeding, Cryopreservation, Quarantine] & Care Products [Cages, Bedding, Feed] – Forecasts to 2018” to its store. Dallas, Texas (PRWEB) January 08, 2014 Over the years, the mice model market, which includes models and services, has witnessed many innovations that have led to an increase in the...

2014-01-06 16:27:45

Plans to submit end of phase II meeting request to FDA SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Phase IIb Kinect 2 study. The pre-specified primary endpoint was the change-from-baseline in the Abnormal Involuntary Movement Scale (AIMS) at Week 6 as assessed by central...

2013-12-27 12:22:29

Non-profit provides tens of millions in grants since founding by Barbara and Edward Netter in 2001 STAMFORD, Conn., Dec. 27, 2013 /PRNewswire/ -- As the potential of gene and cell therapy in fighting cancers grows and oncologists across the nation explore the burgeoning science, doctors have uncovered a stunning development - cancers can be treated using patients' own cells as a weapon, and can eliminate the harrowing, often debilitating effects of chemotherapy, radiation and surgery. (Photo:...

2013-12-24 13:28:00

Working in mice, researchers at Washington University School of Medicine in St. Louis report developing a gene delivery method long sought in the field of gene therapy: a deactivated virus carrying a gene of interest that can be injected into the bloodstream and make its way to the right cells. In this early proof-of-concept study, the scientists have shown that they can target tumor blood vessels in mice without affecting healthy tissues. "Most current gene therapies in humans involve...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related